Literature DB >> 26333950

Tumefactive demyelinating lesions as a first clinical event: Clinical, imaging, and follow-up observations.

In Hye Jeong1, Su-Hyun Kim1, Jae-Won Hyun1, AeRan Joung1, Hyo-Jin Cho1, Ho Jin Kim2.   

Abstract

BACKGROUND: Tumefactive demyelinating lesions (TDLs) are associated with a variety of demyelinating diseases in the central nervous system (CNS). However, there are no current guidelines describing how to classify and treat patients with this rare phenotype. Thus, the present study aimed to determine the long-term evolution and disease course of patients initially presenting with TDLs and to describe their clinical and radiographic characteristics.
METHODS: From the National Cancer Center registry of inflammatory diseases of the CNS, 31 patients initially presenting with TDLs with follow-up for at least 12 months were enrolled and their demographic, clinical, and radiographic characteristics were evaluated.
RESULTS: The median follow-up duration was 37.6 months, during which time 11 patients were diagnosed with neuromyelitis optica spectrum disorder (NMOSD), seven with multiple sclerosis (MS), and 11 remained idiopathic; six did not experience any further clinical events (isolated demyelinating syndrome), and five patients experienced recurrent demyelinating events that were not consistent with either MS or NMOSD. Of the remaining two patients, one was diagnosed with hyperthyroidism-associated demyelination and one with tacrolimus-induced demyelination.
CONCLUSIONS: The majority of TDLs evolve into MS or NMOSD. However, despite extensive diagnostic work-ups and long-term follow-ups, the etiology of TDLs was unknown for some patients.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Anti-aquaporin-4 antibody; Inflammatory demyelinating disease; Isolated demyelinating syndrome; Multiple sclerosis; Neuromyelitis optica spectrum disorder; Tumefactive demyelinating lesions

Mesh:

Year:  2015        PMID: 26333950     DOI: 10.1016/j.jns.2015.08.034

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  11 in total

1.  Reversible disconnection syndrome in a case of acute tumefactive demyelinating lesion: a PET study.

Authors:  Carlotta Chiavazza; Angelina Cistaro; Piercarlo Fania; Antonio Bertolotto; Paola Cavalla; Roberta Rudà; Lorenzo Pinessi; Riccardo Soffietti
Journal:  Neurol Sci       Date:  2016-07-25       Impact factor: 3.307

Review 2.  Pattern Recognition of the Multiple Sclerosis Syndrome.

Authors:  Rana K Zabad; Renee Stewart; Kathleen M Healey
Journal:  Brain Sci       Date:  2017-10-24

3.  Population-based incidence and clinico-radiological characteristics of tumefactive demyelination in Olmsted County, Minnesota, United States.

Authors:  Mahboubeh Fereidan-Esfahani; Paul A Decker; Jeanette E Eckel Passow; Claudia F Lucchinetti; Eoin Patrick Flanagan; William Oliver Tobin
Journal:  Eur J Neurol       Date:  2021-12-09       Impact factor: 6.089

4.  Clinical and imaging correlation in patients with pathologically confirmed tumefactive demyelinating lesions.

Authors:  Matthew A Tremblay; Javier E Villanueva-Meyer; Soonmee Cha; Tarik Tihan; Jeffrey M Gelfand
Journal:  J Neurol Sci       Date:  2017-08-10       Impact factor: 3.181

5.  Commentary: Tumefactive Demyelinating Lesions as a First Clinical Event: Clinical, Imaging, and Follow-up Observations.

Authors:  Tatiana Koudriavtseva; Domenico Plantone
Journal:  Front Neurol       Date:  2016-12-05       Impact factor: 4.003

6.  Chinese Guidelines for the Diagnosis and Management of Tumefactive Demyelinating Lesions of Central Nervous System.

Authors: 
Journal:  Chin Med J (Engl)       Date:  2017-08-05       Impact factor: 2.628

7.  Natalizumab is Effective for the Treatment of Relapsing-remitting Tumefactive Multiple Sclerosis.

Authors:  Masataka Nakamura; Kumi Itani; Kousuke Miyake; Takenobu Kunieda; Satoshi Kaneko; Hirofumi Kusaka
Journal:  Intern Med       Date:  2017-01-15       Impact factor: 1.271

8.  Tumefactive multiple sclerosis versus high-grade glioma: A diagnostic dilemma.

Authors:  Heath David French
Journal:  Surg Neurol Int       Date:  2021-05-03

Review 9.  A challenging diagnosis of late-onset tumefactive multiple sclerosis associated to cervicodorsal syringomyelia: doubtful CT, MRI, and bioptic findings: Case report and literature review.

Authors:  Renata Conforti; Raffaella Capasso; Rosario Galasso; Mario Cirillo; Gemma Taglialatela; Luigi Galasso
Journal:  Medicine (Baltimore)       Date:  2016-09       Impact factor: 1.889

10.  Progression of tumefactive demyelinating lesion in a child demonstrated with MRI.

Authors:  Marta De Simone; Barbara Brogna; Daniele Litterio Spitaleri; Giulio Cicarelli; Roberta Fantozzi; Bruno Guida
Journal:  Radiol Case Rep       Date:  2017-12-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.